The University of Wisconsin-Madison (UW Madison) has been selected as one of the first test sites in the country for the large Phase 3 AZD1222 clinical trial, investigating AstraZeneca’s experimental vaccine originally developed by the University of Oxford. Led by principal investigator Dr. William Hartman, the prominent midwestern university is targeting 1,600 participants with a need for inclusion of minority groups, such as African Americans and Hispanics as they have been disproportionately impacted by COVID-19. The first volunteer at UW Madison to sign up for the investigational vaccine actually works there as an emergency medicine physician Dr. Jeff Pothof, who declared recently for local media that it's his responsibility to give back and help contribute to beating COVID-19.
TrialSite has reported that the vaccine candidate under investigation for this critical Phase 3 study is the subject of growing chatter that it actually may be under consideration for emergency use authorization. Interestingly, TrialSite observed an unprecedented compression of timeline between estimated start date and primary completion date of 3.5 months for the investigation of AZD1222.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).